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Introduction
In 1997 the World Health Organization (WHO), the International Union Against Tuberculosis
and Lung Disease (IUATLD) and partners world-wide released the first report of the global
project on anti-tuberculosis drug resistance.
1 The data generated in this report were reinforced in
a recently published second report.
2 Directly observed treatment short-course (DOTS), the WHO
strategy for TB control cures virtually all patients with drug-susceptible TB and some drug-
resistant TB through the administration of short-course chemotherapy with first-line drugs.
3
However, patients with  multidrug-resistant (MDR) tuberculosis (TB) to at least  isoniazid and
rifampicin are more likely to fail short-course chemotherapy.  In recent years there has been
encouraging evidence that patients with MDR TB can be cured with appropriate management
based on second-line drugs.
4-6 Unfortunately, second-line drugs are inherently more toxic and
less effective than first-line drugs and reliable assessment of drug resistance is an essential pre-
requisite for appropriate use. Treatment is prolonged and significantly more expensive. Accurate
laboratory drug susceptibility testing (DST) data to second-line drugs will support clinical
decision making and help to prevent the emergence of further drug resistance in patients with
MDR TB.
In order to meet the challenges posed by MDR TB, the WHO established the DOTS-Plus
initiative to assess the feasibility and cost-effectiveness of using second-line drugs to manage
patients with MDR TB primarily in middle and low-income countries.
7 Reliable DST, including
second-line drug testing, is a basic requirement of the DOTS-Plus strategy.  Program officers and
clinicians may not be aware that the intrinsic accuracy of susceptibility testing results (performed
under the best circumstances) varies with the drug tested: it is most accurate for rifampicin and
isoniazid and less for streptomycin and ethambutol.
8 Data of comparable quality for classical
second-line drugs are often fragmentary.
Second-line DST is unnecessary in first-line drug-susceptible cases. In the absence of drug
resistance, first-line drugs are highly effective and second-line drugs should not be used except
in the context of severe drug intolerance.
To ensure accuracy of in-vitro susceptibility results for second-line drugs only laboratories with
experience and well-documented competency in performing first-line drug testing should
consider offering testing for second-line drugs. Consideration should be given to centralising
these analyses where appropriate. For example, a large body of clinical and bacteriological data
exists for early trial drugs such as p-aminosalicylic acid (PAS) but little exists for the use of
fluoroquinolones and other new agents in the management of TB.
In preparing this document the writing committee has tried to indicate the degree of evidence
supporting our recommendations regarding appropriate methodologies for the analysis of
second-line drug resistance.2
Objectives for guidelines
•  To guide TB programme managers and physicians in the appropriate use of second-line drug-
susceptibility testing data
•  To permit determination of the true scope of second-line drug resistance for surveillance
purposes, in the long term
Objectives for the laboratory
•  To recommend standardised methodologies and protocols for second-line DST
•  To recommend appropriate classes of drugs for DST
•  To recommend the scope of internal quality control measures that should be undertaken by
laboratories performing second-line DST
•  To provide a framework for the evaluation of new therapeutic compounds
 
Technical Issues
1. Drugs to be tested
Second-line drugs considered in these guidelines are those listed in the WHO Guidelines for the
Management of Drug Resistant Tuberculosis.
9  This list comprises the following drugs:
§  Aminoglycosides for Kanamycin and Amikacin
§  Polypeptides for Capreomycin, Viomycine, and Enviomycin
§  Fluoroquinolones for Ofloxacine, and Ciprofloxacine
§  D-cycloserine (Terizidone)
§  Ethionamide, Prothionamide
§  p-aminosalicylic acid (PAS)
When several drugs are mentioned for a class, only one of them needs to be tested because of
complete cross-resistance between members of that class. Testing selection within a class is not
to be considered as a recommendation for preferential clinical use.
2. Standard method:  Löwenstein Jensen
Criteria for drug resistance testing on Löwenstein Jensen (L-J) using the proportion method have
been elaborated for all drugs listed above except for fluoroquinolones.
10,11 The following
recommendations apply to indirect susceptibility testing of pure cultures of  Mycobacterium3
tuberculosis (M. tuberculosis). Other testing methods like the resistance ratio or the absolute
concentration method might also be considered, if based on published evidence. Other variants
of the proportion method such as those performed in Middlebrook 7H10, 7H11, 7H12 (Bactec
460TB) media can be similarly considered.
3. Concentrations
Drugs used for susceptibility testing should never be from the medicine used for treatment but
pure compounds only, available from the manufacturer.  The recommended critical
concentrations ( mg/ml) and critical proportions for the proportion method on L-J are the
following:
Recommended critical concentrations (µg/ml) and critical proportions for susceptibility
testing for the 2
nd line drugs using the proportion method in L-J medium.
Drug concentrations (µg/ml)
Drugs 1% critical
proportion
10% critical
proportion
Solvents Diluents
Stock
Solutions
(%)
Capreomycin 40 20 DW DW 1
Cycloserine 40 30 DW DW 1*
Kanamycin 30 20 DW DW 1
Ofloxacine§ 2 - 0.1N
NaOH DW 1
PAS 0.5 0.25 DW DW 1*
Protionamide 40 20 DMSO DW 1*
Thioacetazone - 2 TG TG 1*
DW=Sterile distilled water; DMSO=dimethyl-sulfoxide; TG=triethylene glycol or propylene glycol.
* Stock solutions of these drugs should be prepared freshly each time. Stock solutions of other drugs can be stored at 4°
C for up to 1 month.  The necessary amounts of drug should be calculated taking account of molecular formula and potency
informed from the manufacturer. Drug containing media can be stored at 4° C for up to 1 month.
§ Only one concentration and its corresponding resistance criterium for ofloxacin are recommended because data are
only available under these conditions.4
4. Media preparation, dilutions, inoculation, incubation, and reading
For more details on this section please consult
Preparation of the media, bacterial suspensions and dilutions, inoculation of the media,
incubation, reading schedule and reporting are those recommended for first line-drugs.  In short,
Lowenstein-Jensen (L-J) without potato starch with drugs incorporated before  inspissation is
used. The modification of the International Union Against Tuberculosis (IUAT) is
recommended.
12-14  Screw-capped tubes 17 mm in diameter, containing 7 ml of medium are
inspissated at 85
oC during 40-45 minutes. L-J medium with and without incorporated drugs can
be stored at 4
o C for one month.
The indirect drug susceptibility test is carried out from a primary isolation  or a sub-culture on L-
J medium. A representative portion of the culture is obtained by sampling as many colonies as
possible within 1 or 2 weeks after appearance of growth. The sample is homogenised in a sterile
screw-capped bottle (e.g. 14 ml McCartney bottle or 5 ml Bijoux bottle) containing  1 ml H 2O
and 10 glass beads 3.0 mm in diameter.  The mixture is homogenized on a Vortex mixer for up
to a minute and if needed the opacity is adjusted by the addition of sterile, distilled H 2O, down to
that of a standard suspension of 1.0 mg/ml of BCG. The suspension is left to settle for about 30
minutes.
There are two recommended methods of medium inoculation:
In the first one, serial dilutions of  10
-1 mg/ml to 10
-5 mg/ml of the standard suspension are
prepared by diluting sequentially 1.0 ml of the standard suspension (1 mg/ml) in tubes containing
9 ml of sterile distilled H 2O.  Dilutions of 10
-3 mg/ml and 10
-5 mg/ml are inoculated on L-J and
on  drug containing L-J medium.  For each isolate, two bacterial dilutions of the suspension are
made; for each dilution of the suspension two control tubes are inoculated and one tube is
inoculated for each drug concentration prepared. Therefore, for each drug 8 tubes have to be
inoculated in total. The volume of the inoculum is 0.2 ml.
The second method uses calibrated inoculating loops. Two dilutions - 10
-2 mg/ml and 10
-4 mg/ml
- are made from the standard suspension by  serially diluting a loopful  (0.01 ml) into two screw-
capped tubes (14 ml  McCartney bottle or 5 ml Bijoux bottle) containing 1.0 ml of sterile,
distilled H2O. The inoculation of tubes is identical to the one described above, but the inoculum
is a loopful (0.01 ml) of each dilution.
 
After inoculation, the tubes are incubated at 37
o C in a slanted position, with the screw caps
slightly loosened to allow for the evaporation of the inoculum . After 24-48 hours, screw caps
are tightened and the tubes are further incubated.
The reading of results consists of three simple steps:
-  the counting of colonies grown on the different slants
-  the calculation of the proportion of resistant bacilli by comparing counts on drug free and
drug containing L-J medium;
-  the matching of the calculated proportion with the critical proportion of the drug in question
to determine if the proportion is higher (resistant strain) or lower (susceptible strain).5
The reading of results is carried out at the 28
th and 40
th day after inoculation. If at the 28
th day
reading, the proportion of resistant colonies is higher than the critical proportion, the strain can
be reported as resistant. Also, if at the 28
th day reading, there are no colonies on the lowest drug
concentration  inoculated with the richest dilution used, the strain can be reported as susceptible
without further reading. Except for these two circumstances, all other results should be reported
after the 40
th day reading.
The results should be reported as “susceptible” or “resistant” only, to facilitate the interpretation
by clinicians. The percentages of resistant mutants have to be kept in the labs for possible future
reference.
5. Internal quality control procedures for drug susceptibility testing of M. tuberculosis
by the proportion method on L-J.
Internal quality control of the media is an essential part of DST.  Quality control tests should be
carried out for each batch of medium produced. The recommended procedure includes the use of
a reference strain i.e. H37Rv sensitive to all drugs tested. Two methods are recommended for
internal quality control. One involves the plating of serial inoculation dilutions, which will detect
the number of naturally occurring resistant mutants (test-undiluted suspensions and serial
dilutions -1, -2, -3). The other one involves the use of serial drug concentrations to determine
variations in minimal inhibitory concentrations.
Batches of media for DST should be kept at 4° C for no longer than 4 weeks.
5.1 Quality control of medium batches.
The test, carried out with the M.tuberculosis reference strain H37 Rv, consists in determining for
each drug and each drug concentration used, the proportion of drug resistant bacilli in this strain.
If this proportion falls between the set limits indicated in Table I, the medium can be considered
as satisfactory. Is this is not the case, a new batch has to be produced and all tests repeated. As
this proportion is very low, the quality control test differs slightly from the regular drug
susceptibility test. The following dilutions of the standard bacterial suspension (1 mg/ml) are
inoculated on a control tube and on a tube of each drug concentration tested:
1, 10
-1, 10
-2, 10
-3 mg / ml
The following dilutions of the standard bacterial suspension (1 mg/ml) are inoculated on two
control tubes:
10
-5 and 10
-6 mg / ml
The definitive reading of the test is done on the 28
th and 40
th day of incubation at 37°
 C. Colony6
counting and the calculation of proportions are carried out as in a regular drug susceptibility test.
This test should be carried out on each new batch of media.
5.2 Quality control of the validity of drug resistance criteria in the laboratory
This test is identical to the one described above except for the fact that it is carried out on five
randomly selected “wild type” strains of  M.tuberculosis. If the proportion of resistant bacilli in
four out of the five selected “wild type” strains falls within the limit proportions shown on Table
II, the recommended drug resistance criteria of the proportion method on L-J are validated.
Accepting four of five “wild type” strains, allows for the low (but always possible) probability to
pick a drug resistant strain, as one takes five “wild type” strains randomly nowadays. In practice
only the four following drugs need to be tested: isoniazid, streptomycin, PAS and ethionamide.
It is reasonable to test only four drugs, since the criteria will likely be met for the other drugs.
This is a time saving recommendation; however, laboratories are also welcome to test all drugs.
The performance of this quality control test is indicated in the following circumstances:
v  a few months after a laboratory begins testing for TB drug susceptibility, to make sure that a
routine likely to be reproducible is attained in a laboratory which is just starting DST,
v  every so often, in order to identify possible undetected changes in the growth characteristics
of strains seeded on drug containing media,
v  When strains isolated from untreated TB cases show an unusually high frequency of drug
resistance.  Testing on different batches of drug containing media is certainly a good way to
check the validity of the original results
Good laboratory practice dictates that this test be performed at least semi-annually, preferably
quarterly.  It is important to state that when a laboratory starts DST, a linkage should be
established with an external laboratory for quality control purposes.7
Table I. Maximum, median and minimum number of drug resistant mutants in the H37Rv
strain per 10
-6 bacilli. Reading at 40 days of incubation.
*  The proportion of PAS and ethionamide resistant mutants in the H 37Rv strain is much
higher than in regular “wild type” strains.
Isoniazid CONC. ( µg /ml )    0.1    0.2   1.0
Minimum          2         0 0
Median          2         4 2
Maximum      150       32 14
Streptomycin CONC. ( µg /ml )    2.0    4.0   8.0
Minimum          6         0 0
Median      460         7 0
Maximum 37,000     300 3
PAS* CONC. ( µg /ml )    0.25    0.5   1.0
Minimum    2,000        17         1
Median  38,000      900       22
Maximum 700,000 50,000     450
Ethionamide* CONC. ( µg /ml )  10.0  20.0  30.0
Minimum   12,500      120       38
Median   95,000   3,500     400
Maximum 700,000 70,000  8,200
Cycloserine CONC. ( µg /ml )   20.0  30.0  40.0
Minimum        21          0         0
Median      450          4         2
Maximum 10,000      600     300
Viomycin CONC. ( µg /ml )   20.0  30.0   40.0
Minimum          28          0         0
Median     1,800      100       12
Maximum 100,000 10,000     350
Kanamycin CONC. ( µg /ml )   10.0  20.0   30.0
Minimum        900          1        0
Median     6,200        80        7
Maximum 400,000   4,000    1508
Table II. Maximum, median and minimum number of drug resistant mutants in “wild
type” strains of M.tuberculosis strain per 10
-6 bacilli. Reading at 40 days of incubation.
5.3 Quality control using serial drug concentrations to determine variations in minimal
inhibitory concentrations.
For quality testing of each lot of culture medium, the minimal inhibitory concentration (MIC) of
M. tuberculosis H37Rv shall be determined.
6. Storage of mycobacteria in 10% skim milk solution.
i)  Reconstitute skim milk powder in distilled water (100 grams per litre).
ii)  Dispense 1.6 ml into 1 oz. McCartney bottles containing 10 glass beads.
iii)  Autoclave at 15 lbs. and 121
o C. for about 10 minutes. Tighten caps after cooling
(Medium can be frozen at this stage).
Isoniazid CONC. ( µg /ml )    0.1    0.2   1.0
Minimum            2          0.5       0
Median          41          5       3
Maximum        180        41     12
Streptomycin CONC. ( µg /ml )    2.0    4.0   8.0
Minimum        100          0.7       0
Median     5,000        40       2
Maximum 100,000      400     12
PAS CONC. ( µg /ml )    0.25    0.5   1.0
Minimum            1          0.1       0
Median        800        25       5
Maximum   11,000       100     32
Ethionamide CONC. ( µg /ml )  10.0  20.0  30.0
Minimum     6,000       100       0
Median   30,000    1,500   100
Maximum   80,000    5,000   5009
iv)  Add bacterial growth from 1 slope of L-J medium with 3+ growth.
v)  Mix on Vortex mixer for about 30 seconds.
vi)  Allow foam to subside for 2 hours.
vii)  Pipette bacterial suspension into 1 cryovial (Nalgene 2.0 ml).
viii)  Freeze at –20 
0C until needed.
To use frozen vials
i)  Thaw cryovial at room temperature.
ii)  Pipette 2 or 3 drops onto a slant of medium and incubate at appropriate temperature.
iii)  Vials can be re-frozen 2 or 3 times.
7. Repository for well characterised strains
When a new method is validated, it is imperative that a large number of strains (several
hundreds), including both drug-susceptible and -resistant, are tested at several sites and the
results compared with a previously validated method.  In addition, it is warranted that these
strains should be well characterised, i.e., identified as susceptible or resistant, and if resistant,
their mutation(s) identified.  Further, to prevent any bias in the study, it is important that the
strains are shown to be genetically dissimilar through DNA fingerprinting.  Acquiring the
background information on the strains will require close collaboration between laboratories,
clinicians, and TB control officers.  Only a few institutions have access to such well-
characterised strains, and therefore, a repository of frozen strains should be formally organised
and aliquots made available to evaluating laboratories.  This approach would allow different
procedures to be compared over time in different laboratories using the same group of well-
characterised strains.
8. Further needs for research
Our knowledge today is very incomplete regarding how to best perform in vitro susceptibility
testing of newer second-line drugs, and the clinical value of such tests.  Studies to increase our
understanding are needed both regarding methodology - which is the optimal test assay and
breakpoint concentrations for each of the newer drugs? - and regarding the clinical relevance of
such in vitro testing - can the outcome of the addition of a certain drug to a drug regimen in
treating MDR-TB be predicted by it's in vitro susceptibility/resistance?
Some examples of needed research follows:
Methodology:
q  Pyrazinamide -  what is the optimal way to test resistance to this drug? Broth or solid10
medium? pH? Usefulness of enzyme testing such as pyrazinamidase? Other possible markers
of PZA-resistance?
q  quinolones -  which is the best representative to test in this group, ofloxacin or
ciprofloxacin or another one?
q  quinolones -  how should the test be carried out, solid culture, L-J or agar medium? a
broth based system, Bactec?
q  quinolones - which concentrations should be recommended for testing? Are these the
same for all quinolones?
Similar methodological questions are relevant also for other new and coming drugs.
Clinical relevance:
Standardized outcome studies where in vitro data are analyzed in relation to the improved
clinical outcome for the MDR-TB patients when an individual drug is added to an existing
(standardized?) regimen are needed to document the relevance of in vitro DST.
9. Issues to consider
¤  It is important to report separately results regarding first-line drugs from those of second-line
drugs. This is to emphasise that second-line drugs constitute a second option for the treatment of
TB
¤  For clinical purposes, the utilisation of second-line drugs or new drugs is not justified
without bacteriological confirmation of resistance to first-line drugs.
¤  In patients with a high load of bacilli in sputum and pulmonary cavities, smear microscopy
may persist positive up to 3 months even if M. tuberculosis strain is fully susceptible to first-line
drugs.  Repetition of DST is unnecessary within a 3 month period even in patients with persistent
positive sputum.
¤  In the event of patients with M. tuberculosis susceptible to first-line drugs that show poor
response to directly observed treatment, before switching to another therapeutic option, several
other factors should be investigated: interaction with other drugs (antiretrovirals), absorption,
problems related to intestinal mobility or hepatic metabolism.
¤  Treatment for tuberculosis should follow the current recommendations from the WHO.11
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ANNEX
Sample form to report drug susceptibility testing of Mycobacterium tuberculosis
Name
Age
Sex
Address
Specimen No.: Date:
Smear microscopy results
Culture
Identification:
Susceptibility test (date):
Drug Result
Isoniazid
Rifampicin
Ethambutol
Pyrazinamide
Streptomycin
Second-line drugs: Yes    No
Drug Result
Thioacetazone
Ethionamide
Kanamycin
Cycloserine
Capreomycin
PAS
Ofloxacin13